Aura Biosciences completes Phase 3 CoMpass enrollment, cuts staff 20% to focus on ocular oncology
The company reported 108 patients enrolled in its choroidal melanoma trial, deprioritized its bladder cancer program, and named three new executives while its CFO and legal chief depart.
SEC filing